Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPEED: Penpulimab + CRT for Locally Advanced Esophageal Squamous Cell Cancer
NCT05561699Unknown
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Sep 2022
- Primary completion
- Sep 2024
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Open-label, single-arm trial of penpulimab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Zhongshan Hospital, Fudan University. Primary endpoints: Pathological Complete Remission Rate and Adverse Events and Serious Adverse Events. Status: unknown.
02
Drugs
penpulimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT05561699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05561699.